No­vo Nordisk ramps up le­gal case against com­pound­ing phar­ma­cies sell­ing 'mis­brand­ed' semaglu­tide

No­vo Nordisk is tak­ing an­oth­er Flori­da phar­ma­cy to court af­ter al­leged­ly find­ing im­pu­ri­ties in its com­pound­ed drugs mar­ket­ed as semaglu­tide, in­clud­ing one sam­ple that was 33% im­pure, ac­cord­ing to court doc­u­ments.

It’s the lat­est in a string of law­suits filed by No­vo and its ri­val Eli Lil­ly in an at­tempt to stop well­ness cen­ters and com­pound­ing phar­ma­cies from what they be­lieve is im­prop­er mar­ket­ing of the pop­u­lar di­a­betes and weight loss prod­ucts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER